What’s Ahead for Axogen Incorporated (NASDAQ:AXGN) After Less Shorted Shares?

December 7, 2017 - By Hazel Jackson

 What’s Ahead for Axogen Incorporated (NASDAQ:AXGN) After Less Shorted Shares?

The stock of Axogen Incorporated (NASDAQ:AXGN) registered a decrease of 9.61% in short interest. AXGN’s total short interest was 960,000 shares in December as published by FINRA. Its down 9.61% from 1.06 million shares, reported previously. With 199,700 shares average volume, it will take short sellers 5 days to cover their AXGN’s short positions. The short interest to Axogen Incorporated’s float is 4.16%.

The stock increased 1.34% or $0.35 during the last trading session, reaching $26.45. About 338,153 shares traded or 19.22% up from the average. AxoGen, Inc. (NASDAQ:AXGN) has risen 181.49% since December 7, 2016 and is uptrending. It has outperformed by 164.79% the S&P500.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company has market cap of $901.78 million. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It currently has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage

Among 7 analysts covering AxoGen (NASDAQ:AXGN), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AxoGen had 16 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Hold” rating by Lake Street on Thursday, November 3. As per Tuesday, November 22, the company rating was upgraded by Lake Street. Leerink Swann maintained AxoGen, Inc. (NASDAQ:AXGN) on Tuesday, November 21 with “Outperform” rating. As per Monday, August 21, the company rating was maintained by Cantor Fitzgerald. Wedbush maintained it with “Outperform” rating and $12 target in Monday, November 7 report. The stock of AxoGen, Inc. (NASDAQ:AXGN) earned “Outperform” rating by Wedbush on Friday, August 28. The rating was maintained by Roth Capital on Monday, September 11 with “Buy”. Leerink Swann maintained the stock with “Outperform” rating in Thursday, November 2 report. Zacks upgraded AxoGen, Inc. (NASDAQ:AXGN) rating on Tuesday, August 11. Zacks has “Hold” rating and $4 target. Wedbush maintained AxoGen, Inc. (NASDAQ:AXGN) on Tuesday, November 21 with “Buy” rating.

More recent AxoGen, Inc. (NASDAQ:AXGN) news were published by: Nasdaq.com which released: “AxoGen, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference” on November 14, 2017. Also Streetinsider.com published the news titled: “Jefferies Starts AxoGen, Inc. (AXGN) at Buy, Best Growth Story in Medtech” on November 30, 2017. Streetinsider.com‘s news article titled: “AxoGen, Inc. (AXGN) PT Raised to $27 at JMP Securities Following Analyst Day” with publication date: November 21, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.